The first RCT on the efficacy of anti-IL1 treatments was conducted in 2017, showing the efficacy and safety of anakinra for the treatment of colchicine-resistant FMF compared to a placebo [133]. The gene discussed is IL1A; the disease is familial Mediterranean fever.